March 16th 2023
Look for fluctuating vision, test objectively and keep a few effective tools at your disposal to treat OSD.
January 18th 2023
Identifying herpesvirus DNA in corneal graftsJanuary 10th 2023
Recent research suggests the need for routine HSV-1 and VZV PCR testing in all explanted corneas regardless of clinical suspicion to detect, treat, and prevent possible recurrence of herpes infection in corneal grafts and support graft survival.
2023: What ophthalmologists in Europe anticipate for the year aheadDecember 12th 2022
Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
The pathophysiology and pathomorphology of corneal ectasia: Part 4November 14th 2022
Corneal cross-linking (CXL) is improving all the time, although all protocols retain the basic requirements for oxygen, riboflavin and UV light. Recent developments mean that CXL at the slit lamp is feasible, which will improve access to the procedure.
Comparing dry eye disease in adult and paediatric populations via the IRIS RegistryOctober 1st 2022
Almost 5 million patients in the IRIS Registry had received at least one diagnosis of DED between 2013 and 2019; of those, 203,171 were children under 18 years of age and 4,592,808 were adults.
Corneal ectasia part 3: OCT epithelial thickness measurements allow monitoring of corneal changesSeptember 28th 2022
The epithelium adapts to compensate for changes in the cornea and these changes can be detected with high sensitivity, reducing both false positives and false negatives in the diagnosis of keratoconus.
Circumnavigating the bumpy road to vernal keratoconjunctivitis: Time is keySeptember 19th 2022
Ophthalmologists should look past the eyes in patients presenting with a persistent ocular allergic response and be mindful that sight-threatening vernal keratoconjunctivitis is a possibility.
Top ophthalmologists anticipate ESCRS sessionsSeptember 15th 2022
Members of the Ophthalmology Times Europe Editorial Advisory Board offer comments on the symposia they are most excited to attend at the 2022 ESCRS Congress in Milan, Italy.
RegeneRx, HLB Therapeutics sign letter of intent for Phase 3 clinical trials in neurotrophic keratitisJuly 20th 2022
RegeneRX Biopharmaceuticals and its US joint venture partner and licensee, HLB Therapeutics, signed a letter of intent this week with a global ophthalmology contract research organization to conduct a pair of Phase 3 clinical trials simultaneously beginning in the fall in the US and Europe for patients with neurotrophic keratitis.
Enrolment begins in Phase 2 study for therapeutic for persistent corneal epithelial defectsJuly 10th 2022
Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.
The pathophysiology and pathomorphology of corneal ectasia: Keratoconus will not develop without eye rubbingMay 30th 2022
Eye rubbing is an essential factor in the development of keratoconus. “No rub, no cone” is the rule: a genetic predisposition for the disease will come to nothing without excessive eye rubbing.
Cost of treatment discourages adherence for patients with dry eye disease associated with Sjögren’s syndromeMay 28th 2022
In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment. Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.